logo
Pegasystems (NASDAQ:PEGA) Reports Upbeat Q2 But Stock Drops 11%

Pegasystems (NASDAQ:PEGA) Reports Upbeat Q2 But Stock Drops 11%

Yahoo23-07-2025
Enterprise workflow software provider Pegasystems (NASDAQ:PEGA) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 9.5% year on year to $384.5 million. Its non-GAAP profit of $0.28 per share was 18.2% above analysts' consensus estimates.
Is now the time to buy Pegasystems? Find out in our full research report.
Pegasystems (PEGA) Q2 CY2025 Highlights:
Pega Cloud ACV and total ACV beat
Pega Cloud Backlog and total Backlog beat
Subscription revenue (services + licenses) beat but growth decelerated meaningfully from last quarter
Revenue: $384.5 million vs analyst estimates of $363.1 million (9.5% year-on-year growth, 5.9% beat)
Adjusted EPS: $0.28 vs analyst estimates of $0.24 (18.2% beat)
Operating Margin: 4.5%, in line with the same quarter last year
Free Cash Flow Margin: 21.9%, down from 42.5% in the previous quarter
Market Capitalization: $8.79 billion
'Our unique approach to AI was a key driver of our strong first half results,' said Alan Trefler, Pega founder and CEO.
Company Overview
Founded by Alan Trefler in 1983, Pegasystems (NASDAQ:PEGA) offers a software-as-a-service platform to automate and optimize workflows in customer service and engagement.
Revenue Growth
A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last three years, Pegasystems grew its sales at a 11.1% annual rate. Although this growth is acceptable on an absolute basis, it fell short of our standards for the software sector, which enjoys a number of secular tailwinds.
This quarter, Pegasystems reported year-on-year revenue growth of 9.5%, and its $384.5 million of revenue exceeded Wall Street's estimates by 5.9%.
Looking ahead, sell-side analysts expect revenue to grow 2% over the next 12 months, a deceleration versus the last three years. This projection doesn't excite us and suggests its products and services will face some demand challenges.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Customer Acquisition Efficiency
The customer acquisition cost (CAC) payback period measures the months a company needs to recoup the money spent on acquiring a new customer. This metric helps assess how quickly a business can break even on its sales and marketing investments.
Pegasystems's recent customer acquisition efforts haven't yielded returns as its CAC payback period was negative this quarter, meaning its incremental sales and marketing investments outpaced its revenue. The company's inefficiency indicates it operates in a highly competitive environment where there is little differentiation between Pegasystems's products and its peers.
Key Takeaways from Pegasystems's Q2 Results
We enjoyed seeing Pegasystems beat analysts' revenue and EPS expectations this quarter. Zooming out, we think this quarter featured some important positives. Investors were likely hoping for more, and shares traded down 11% to $45.35 immediately following the results.
So should you invest in Pegasystems right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Yahoo

time22 minutes ago

  • Yahoo

Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts

Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?
Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?

Yahoo

time22 minutes ago

  • Yahoo

Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?

Warren Buffett has struck again – this time in healthcare's rubble. Berkshire Hathaway (NYSE: BRK.B) recently disclosed a five million share position in United Healthcare Group (NYSE: UNH), the nation's largest health insurer. The timing is quintessentially Buffett. UNH shares have plummeted more than 50% from their all-time highs, battered by regulatory pressures and industry headwinds. While most investors flee the carnage, the Oracle of Omaha is doing what he does best – hunting for value in the wreckage. But as with everything Buffett does, context matters. Putting Things in Perspective The United Healthcare position is estimated to be worth around US$1.6 billion based on Berkshire's five million share purchase. That's a sizable sum of money by any measure. Here's what you need to know: Berkshire Hathaway's stock portfolio is worth close to US$295 billion. Therefore, the UNH position is less than 0.6% of the company's overall stock holdings. In contrast, Berkshire's largest position is actually Apple (NASDAQ: AAPL), valued at US$65 billion – representing more than a fifth of the total stock portfolio. Put simply, while the United Healthcare investment grabbed headlines, it wouldn't be moving Berkshire's needle anytime soon. Beyond that, there's a crucial question: did Buffett actually make this call? The Real Decision Makers Every Berkshire Hathaway stock purchase gets dissected as if it came straight from Warren Buffett himself. But the Oracle doesn't fly solo anymore. Berkshire brought on Todd Combs in 2010, followed by Ted Weschler in 2012. Both serve as investment managers with significant autonomy. Initially, Buffett allocated US$2 billion to each manager. By 2017, that figure had quintrupled to US$10 billion per person. Given this structure, the US$1.6 billion UNH bet could be from either Combs or Weschler – not Buffett himself. Get Smart: Look before you leap Context matters when it comes to investing. If you jump in and buy shares without understanding the full picture, you could get hurt in the process. For Berkshire, even if the UnitedHealth investment doesn't work out, you won't see the company sweating over a position worth less than 0.6%. Does the same apply to you? That's food for thought if you decide to pull the trigger. Dive into the future of technology with our newest FREE report, 'The Rise of Titans.' Discover how the big 7 US tech stocks can be your ticket to huge long-term gains. Download your copy today and see how easy it is to supercharge your portfolio. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Chin Hui Leong owns shares of Apple and Berkshire Hathaway The post Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow? appeared first on The Smart Investor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Yahoo

time22 minutes ago

  • Yahoo

Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth

Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store